Nautilus Biotechnology
San Carlos
About Nautilus Biotechnology
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1M – $10M
- Total funding: $303.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2021)
- Ticker: nasdaq:NAUT
- Website: nautilus.bio
- Phone: +1 206 333 2001
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/nautilus-biotechnology-2202 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.